Search results
Results From The WOW.Com Content Network
2002: ICON acquired clinical research provider, BPA. [20] 2003: ICON acquired Medeval, a UK-based Phase I facility, and US consulting firm, Globomax [21] [22] 2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc. [23] 2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group [24]
A Site Management Organization (SMO) is an organization that provides clinical trial-related services to a contract research organization (CRO), a pharmaceutical company, a biotechnology company, a medical device company, or a clinical site.
Far East Organization is the largest private real estate developer in Singapore. [1] [2] Founded in 1960 by Ng Teng Fong, [3] [4] the company has businesses in property development, retail, hospitality, [5] and food and beverage [6] brands in Asia and Australia.
The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, a 2015 Swiss NGO of pharmaceutical companies and others, defined a contract research organization (CRO), specifically pertaining to clinical trials services as: [8]: 10 "A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or ...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, [2] [1] [3] employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
A road sign outside the campus of the Nanyang Technological University (NTU), from Singapore English (2007) ... CRO - Company Routine Orders; CS - Combat Shoot;
Singapore's first publicly funded drug candidate, ETC-159, which was discovered and developed through a collaboration with Duke-NUS Graduate Medical School, advanced into Phase 1 clinical trials in July 2015. This drug targets a number of cancers, including colorectal, ovarian and pancreatic cancers, which contribute to a significant proportion ...